Those are precisely the questions the larger, longer Phase 3 TRIUMPH program is designed to answer, which is why an approval decision waits on it
These two proteins form the structural backbone of firm, elastic skin, and their decline is a major reason skin goes slack after shedding weight
10.1016/S0928-4257(99)00123-0 [DOI] [PubMed] [Google Scholar] Sobrado, M
No receptor-mediated adverse events (e.g., cardiovascular effects, endocrine disruption) have been reported, consistent with NNMT's limited expression outside metabolic tissues
Tp ch Nghin cu Vt liu Sinh hc Phn B: Vt liu Sinh hc ng dng
Full disclaimer 1.AOD-9604 is a 16-amino acid peptide fragment derived from human growth hormone (hGH residues 177-191) with added tyrosine, developed by Metabolic Pharmaceuticals for obesity treatment 2.Proposed mechanism: selective stimulation of lipolysis (fat breakdown) and inhibition of lipogenesis (fat formation) without growth hormone-like effects on IGF-1 or blood glucose 3.Failed Phase 2b clinical trial for obesity (2007)did not demonstrate statistically significant weight loss versus placebo, terminating clinical development for this indication 4.Received FDA "Generally Recognized as Safe" (GRAS) designation in 2023 as a food substance, but this is NOT a drug approval and does not establish efficacy for weight loss 5.Regulatory status: not FDA-approved as a drug, prohibited by WADA, and insufficient evidence for weight loss efficacy
